Oct 2026
Limited Impact of Adjuvant Chemotherapy in ALK-Positive Stage II-III Lung Adenocarcinoma: A Multicenter CReGYT-03 ALK Study.
Akira Hamada, Shinkichi Takamori, Asato Hashinokuchi et al.
· Annals of Surgical Oncology · 0 citations